Scarica l'app Stockscreener
89.51
0.07%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Precedente Chiudi:
$89.57
Aprire:
$88.89
Volume 24 ore:
583.63K
Relative Volume:
0.39
Capitalizzazione di mercato:
$6.32B
Reddito:
-
Utile/perdita netta:
$-100.44M
Rapporto P/E:
-40.32
EPS:
-2.22
Flusso di cassa netto:
$-105.32M
1 W Prestazione:
-1.66%
1M Prestazione:
+30.98%
6M Prestazione:
+398.94%
1 anno Prestazione:
+215.18%
Intervallo 1D:
$88.02
$91.21
Intervallo di 1 settimana:
$87.00
$94.42
Portata 52W:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Nome
Structure Therapeutics Inc Adr
Settore
Industria
Telefono
(650) 457-1978
Indirizzo
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Confronta GPCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
89.51 | 6.33B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-02 | Iniziato | Citigroup | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-21 | Iniziato | JP Morgan | Overweight |
| 2024-04-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-07-27 | Iniziato | Piper Sandler | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2023-02-28 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | Guggenheim | Buy |
| 2023-02-28 | Iniziato | Jefferies | Buy |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
CCG Wealth Management LLC Sells 140,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Raised to "Strong-Buy" at The Goldman Sachs Group - MarketBeat
Understanding the Setup: (GPCR) and Scalable Risk - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Assessing Structure Therapeutics (GPCR) Valuation After Genentech Deal And Growing Obesity Pipeline Confidence - Sahm
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC
Goldman Sachs Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $102 - 富途资讯
Why Structure Therapeutics Stock Is Breaking Out Now - TipRanks
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7% - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
SG Americas Securities LLC Has $1.11 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It" - Finviz
Structure Therapeutics (GPCR) Is Up 26.9% After Strong Obesity Pill Data And $748 Million OfferingWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Finviz
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why - Finviz
Watch Structure Therapeutics CEO Stevens on Pipeline Strategy - Bloomberg.com
Structure Therapeutics Stock Surges Amid Positive Analyst Ratings - StocksToTrade
Janney Capital Management LLC Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
A 10% Owner Of Structure Therapeutics Shed Shares - AOL.com
Structure Therapeutics (NASDAQ:GPCR) Trading 12.2% HigherShould You Buy? - MarketBeat
Price Target Hike Sparks Optimism for Structure Therapeutics - StocksToTrade
Why Structure Therapeutics Shares Are Surging Now - TipRanks
Assessing Structure Therapeutics (GPCR) Valuation After Obesity Trial Progress And Genentech Licensing Deal - Sahm
Structure Therapeutics inks major GLP-1 licensing deal - MSN
The Technical Signals Behind (GPCR) That Institutions Follow - Stock Traders Daily
Can This Stock Double Again in 2026? - Finviz
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - sharewise.com
Genentech Licensing Deal For Oral Obesity Drug CT-996 Might Change The Case For Investing In Structure Therapeutics (GPCR) - Sahm
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 - Finviz
Why Structure Therapeutics Shares Are Surging Higher - TipRanks
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight By Investing.com - Investing.com UK
Structure Therapeutics stock gets BMO Capital’s Outperform rating reaffirmed By Investing.com - Investing.com UK
Genentech makes $100M deal with South City neighbor to clear path for GLP-1 weight-loss drug - The Business Journals
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4%What's Next? - MarketBeat
Voya Investment Management LLC Sells 14,230 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2%Here's Why - MarketBeat
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up - Eastern Progress
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next? - Defense World
Structure Therapeutics Inc Adr Azioni (GPCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):